SCHEMBL562505

SCHEMBL562505

CC(C)(C)OC(=O)N1CC(O)=CC1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.38
MAPK1 P28482 2/20 0.37
HDAC1 Q13547 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
USP2 O75604 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NR1H2 P55055 3/20 0.35
BUB1 O43683 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
KDM1A O60341 1/20 0.35
BCHE P06276 1/20 0.34
DTYMK P23919 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
KLK7 P49862 1/20 0.33
ELANE P08246 1/20 0.33
ADORA1 P30542 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25320664 0.83 ESR2 (0.40) ESR2MAPK1USP2SMN1; SMN2NR1H2
SCHEMBL18593203 0.83 ESR2 (0.35) ESR2MAPK1HDAC1HDAC6USP2
SCHEMBL17803281 0.81 ESR2 (0.38) ESR2MAPK1HDAC1HDAC6USP2
SCHEMBL23107390 0.80 HDAC1 (0.36) ESR2MAPK1HDAC1HDAC6USP2
SCHEMBL23186669 0.76 MAPK1 (0.41) ESR2MAPK1HDAC1HDAC6USP2
SCHEMBL1262020 0.76 ESR2 (0.38) ESR2MAPK1USP2SMN1; SMN2NR1H2
SCHEMBL31218507 0.75 CHRM2 (0.44) ESR2MAPK1HDAC1HDAC6USP2
SCHEMBL14007379 0.75 ESR2 (0.43) ESR2MAPK1HDAC1USP2SMN1; SMN2
SCHEMBL18190504 0.74 KLK7 (0.36) HDAC1HDAC6KDM1ADTYMKKLK7
SCHEMBL4796997 0.74 CHRM2 (0.43) ESR2MAPK1HDAC1HDAC6USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230137-A1 P300/CBP HAT INHIBITORS CONSTELLATION PHARMACEUTICALS INC (US) 2025-07-17 US disclosed
US-20250101016-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2025-03-27 US disclosed
US-20250042905-A1 DIHYDROPYRROLO[3,4-C]PYRAZOLE DERIVATIVES AND THEIR USE IN DIAGNOSIS AC IMMUNE SA (CH) 2025-02-06 US disclosed
EP-4430044-A1 DIHYDROPYRROLO[3,4-C]PYRAZOLE DERIVATIVES AND THEIR USE IN DIAGNOSIS AC Immune SA (CH) 2024-09-18 EP disclosed
EP-3752497-B1 P300/CBP HAT INHIBITORS CONSTELLATION PHARMACEUTICALS INC (US) 2024-07-17 EP disclosed
EP-3752497-B1 P300/CBP HAT INHIBITORS CONSTELLATION PHARMACEUTICALS INC (US) 2024-07-17 EP disclosed
US-11964971-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2024-04-23 US disclosed
EP-4327809-A2 TYK2 INHIBITORS AND USES THEREOF Takeda Pharmaceutical Company Limited (JP) 2024-02-28 EP disclosed
CN-112218857-B P300/CBP HAT inhibitors and methods of use thereof 星座制药公司 2023-11-21 CN disclosed
EP-3344624-B1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI INC (US) 2023-10-25 EP disclosed
US-20150126490-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-05-07 US disclosed
US-20150126490-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-05-07 US disclosed
US-20150126490-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-05-07 US disclosed
WO-2015066188-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-05-07 WO disclosed
WO-2015066188-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-05-07 WO disclosed
US-8759341-B2 Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-06-24 US disclosed
EP-2398790-B1 BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF BAYER IP GMBH (DE) 2013-07-03 EP disclosed
US-20120035409-A1 BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2012-02-09 US disclosed
EP-2398790-A1 BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF Bayer Pharma Aktiengesellschaft (DE) 2011-12-28 EP disclosed
WO-2010094405-A1 BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150126490-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS ABL1, MAP3K12, MAP3K2 ESR2 2554/4885MAPK1 95/4885HDAC1 282/4885
US-20250101016-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 ESR2 1662/4885MAPK1 3807/4885HDAC1 1553/4885
US-11964971-B2 Methods and compositions for modulating splicing RBM17, SF3B1, SF3B5 ESR2 1662/4885MAPK1 3807/4885HDAC1 1553/4885
US-20120035409-A1 BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF MET, RET, ERBB2 ESR2 1994/4885MAPK1 924/4885HDAC1 1988/4885
US-20250230137-A1 P300/CBP HAT INHIBITORS EP300, HDAC1, KAT2A ESR2 1042/4885MAPK1 1006/4885HDAC1 2/4885
US-20250042905-A1 DIHYDROPYRROLO[3,4-C]PYRAZOLE DERIVATIVES AND THEIR USE IN DIAGNOSIS SNCA, PARK7, MAPT ESR2 4830/4885MAPK1 781/4885HDAC1 3283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.